Published in Pharmaceuticals (Basel) on November 09, 2012
Deficiency of the novel exopolyphosphatase Rv1026/PPX2 leads to metabolic downshift and altered cell wall permeability in Mycobacterium tuberculosis. MBio (2015) 0.84
Response mechanisms of bacterial degraders to environmental contaminants on the level of cell walls and cytoplasmic membrane. Int J Microbiol (2014) 0.84
Mechanisms of Resistance to Aminoglycoside Antibiotics: Overview and Perspectives. Medchemcomm (2015) 0.82
Sterilizing activity of thioridazine in combination with the first-line regimen against acute murine tuberculosis. Antimicrob Agents Chemother (2014) 0.78
Combined Bioinformatic and Rational Design Approach To Develop Antimicrobial Peptides against Mycobacterium tuberculosis. Antimicrob Agents Chemother (2016) 0.76
Potential of Zanthoxylum leprieurii as a source of active compounds against drug resistant Mycobacterium tuberculosis. BMC Complement Altern Med (2017) 0.75
Linezolid dose that maximizes sterilizing effect while minimizing toxicity and resistance emergence for tuberculosis. Antimicrob Agents Chemother (2017) 0.75
Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature (1998) 60.62
Molecular basis of bacterial outer membrane permeability. Microbiol Rev (1985) 17.75
Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet (1993) 16.75
Molecular basis of bacterial outer membrane permeability revisited. Microbiol Mol Biol Rev (2003) 13.49
The envelope of mycobacteria. Annu Rev Biochem (1995) 9.33
An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun (1996) 9.21
Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol (2002) 8.90
Identification of the outer membrane protein of E. coli that produces transmembrane channels in reconstituted vesicle membranes. Biochem Biophys Res Commun (1976) 7.31
Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods (2001) 7.08
Nonreplicating persistence of mycobacterium tuberculosis. Annu Rev Microbiol (2001) 7.05
Rv3133c/dosR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosis. Mol Microbiol (2003) 5.68
The envelope layers of mycobacteria with reference to their pathogenicity. Adv Microb Physiol (1998) 5.08
Exploring drug-induced alterations in gene expression in Mycobacterium tuberculosis by microarray hybridization. Proc Natl Acad Sci U S A (1999) 4.33
The challenge of new drug discovery for tuberculosis. Nature (2011) 4.23
Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis (2009) 4.22
Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis. Tuberculosis (Edinb) (2003) 4.16
Metabolite-enabled eradication of bacterial persisters by aminoglycosides. Nature (2011) 4.06
Multiple molecular mechanisms for multidrug resistance transporters. Nature (2007) 3.96
Efflux-mediated drug resistance in bacteria. Drugs (2004) 3.90
ATP-binding cassette transporters in bacteria. Annu Rev Biochem (2004) 3.88
Structure and mechanism of ABC transporter proteins. Curr Opin Struct Biol (2007) 3.79
The Escherichia coli ATP-binding cassette (ABC) proteins. Mol Microbiol (1998) 3.77
Effect on solute size on diffusion rates through the transmembrane pores of the outer membrane of Escherichia coli. J Gen Physiol (1981) 3.72
Identification of the protein producing transmembrane diffusion pores in the outer membrane of Pseudomonas aeruginosa PA01. Biochim Biophys Acta (1979) 3.70
The action of antituberculosis drugs in short-course chemotherapy. Tubercle (1985) 3.69
Properties of the large ion-permeable pores formed from protein F of Pseudomonas aeruginosa in lipid bilayer membranes. Biochim Biophys Acta (1981) 3.65
Interpreting cell wall 'virulence factors' of Mycobacterium tuberculosis. Trends Microbiol (2001) 3.58
Disclosure of the mycobacterial outer membrane: cryo-electron tomography and vitreous sections reveal the lipid bilayer structure. Proc Natl Acad Sci U S A (2008) 3.45
Microbial genome analyses: comparative transport capabilities in eighteen prokaryotes. J Mol Biol (2000) 3.43
Mycobacterial stationary phase induced by low oxygen tension: cell wall thickening and localization of the 16-kilodalton alpha-crystallin homolog. J Bacteriol (1998) 3.43
Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell (2011) 3.42
Efflux-mediated drug resistance in bacteria: an update. Drugs (2009) 3.18
Protein kinase G from pathogenic mycobacteria promotes survival within macrophages. Science (2004) 3.16
Streptomycin accumulation in susceptible and resistant strains of Escherichia coli and Pseudomonas aeruginosa. Antimicrob Agents Chemother (1976) 3.01
Drugs versus bugs: in pursuit of the persistent predator Mycobacterium tuberculosis. Nat Rev Microbiol (2008) 2.97
Mycobacterium bovis BCG response regulator essential for hypoxic dormancy. J Bacteriol (2002) 2.94
Mycobacterial cell wall: structure and role in natural resistance to antibiotics. FEMS Microbiol Lett (1994) 2.73
The ATP binding cassette (ABC) transport systems of Mycobacterium tuberculosis. FEMS Microbiol Rev (2000) 2.71
Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2003) 2.71
Direct visualization of the outer membrane of mycobacteria and corynebacteria in their native state. J Bacteriol (2008) 2.60
Permeability barrier to hydrophilic solutes in Mycobacterium chelonei. J Bacteriol (1990) 2.44
Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J Antimicrob Chemother (2003) 2.44
Mycobacterium tuberculosis and the environment within the phagosome. Immunol Rev (2007) 2.42
The future challenges facing the development of new antimicrobial drugs. Nat Rev Drug Discov (2002) 2.36
Gene expression profile of Mycobacterium tuberculosis in a non-replicating state. Tuberculosis (Edinb) (2004) 2.33
Gentamicin accumulation by sensitive strains of Escherichia coli and Pseudomonas aeruginosa. J Antibiot (Tokyo) (1975) 2.21
Practical applications and feasibility of efflux pump inhibitors in the clinic--a vision for applied use. Biochem Pharmacol (2006) 2.14
Mycobacterium tuberculosis: success through dormancy. FEMS Microbiol Rev (2012) 2.07
Determination of ion permeability through the channels made of porins from the outer membrane of Salmonella typhimurium in lipid bilayer membranes. J Membr Biol (1980) 2.07
Mycobacterial porins--new channel proteins in unique outer membranes. Mol Microbiol (2003) 2.04
Role of mycobacterial efflux transporters in drug resistance: an unresolved question. FEMS Microbiol Rev (2006) 2.02
The Mycobacterium tuberculosis iniA gene is essential for activity of an efflux pump that confers drug tolerance to both isoniazid and ethambutol. Mol Microbiol (2005) 1.94
Lipoarabinomannan and related glycoconjugates: structure, biogenesis and role in Mycobacterium tuberculosis physiology and host-pathogen interaction. FEMS Microbiol Rev (2011) 1.88
Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. Am J Respir Crit Care Med (2011) 1.87
Cloning of the mspA gene encoding a porin from Mycobacterium smegmatis. Mol Microbiol (1999) 1.84
MspA provides the main hydrophilic pathway through the cell wall of Mycobacterium smegmatis. Mol Microbiol (2001) 1.79
Persistent and dormant tubercle bacilli and latent tuberculosis. Front Biosci (2004) 1.74
A balancing act: efflux/influx in mycobacterial drug resistance. Antimicrob Agents Chemother (2009) 1.74
Molecular cloning and characterization of Tap, a putative multidrug efflux pump present in Mycobacterium fortuitum and Mycobacterium tuberculosis. J Bacteriol (1998) 1.72
Structural and functional characterization of OmpF porin mutants selected for larger pore size. II. Functional characterization. J Biol Chem (1996) 1.72
Letting sleeping dos lie: does dormancy play a role in tuberculosis? Annu Rev Microbiol (2010) 1.66
Rv2686c-Rv2687c-Rv2688c, an ABC fluoroquinolone efflux pump in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2004) 1.64
Identification of outer membrane proteins of Mycobacterium tuberculosis. Tuberculosis (Edinb) (2008) 1.63
Mycolic acid structure determines the fluidity of the mycobacterial cell wall. J Biol Chem (1996) 1.63
Clinically relevant mutations that cause derepression of the Neisseria gonorrhoeae MtrC-MtrD-MtrE Efflux pump system confer different levels of antimicrobial resistance and in vivo fitness. Mol Microbiol (2008) 1.61
Cell-wall alterations as an attribute of Mycobacterium tuberculosis in latent infection. J Infect Dis (2003) 1.60
Nutrient-starved, non-replicating Mycobacterium tuberculosis requires respiration, ATP synthase and isocitrate lyase for maintenance of ATP homeostasis and viability. Microbiology (2009) 1.60
Differential antibiotic susceptibilities of starved Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother (2005) 1.55
Porins in the cell wall of mycobacteria. Science (1992) 1.54
Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. Antimicrob Agents Chemother (2011) 1.50
Active efflux of fluoroquinolones in Mycobacterium smegmatis mediated by LfrA, a multidrug efflux pump. J Bacteriol (1996) 1.50
Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob Agents Chemother (1996) 1.48
Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis. J Antimicrob Chemother (2010) 1.47
Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis. PLoS One (2012) 1.46
Foundations of antibiotic resistance in bacterial physiology: the mycobacterial paradigm. Trends Microbiol (2006) 1.45
Role of porins for uptake of antibiotics by Mycobacterium smegmatis. Antimicrob Agents Chemother (2008) 1.44
Characterization of P55, a multidrug efflux pump in Mycobacterium bovis and Mycobacterium tuberculosis. Antimicrob Agents Chemother (2001) 1.44
Mechanisms of pyrazinamide resistance in mycobacteria: importance of lack of uptake in addition to lack of pyrazinamidase activity. Microbiology (1999) 1.42
Polyamines decrease Escherichia coli outer membrane permeability. J Bacteriol (1996) 1.40
Mechanisms involved in the development of resistance to fluoroquinolones in Escherichia coli isolates. J Antimicrob Chemother (1999) 1.39
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth. Antimicrob Agents Chemother (2009) 1.38
Mycobacterium tuberculosis lipoprotein LprG (Rv1411c) binds triacylated glycolipid agonists of Toll-like receptor 2. Nat Struct Mol Biol (2010) 1.36
The capsule of Mycobacterium tuberculosis and its implications for pathogenicity. Tuber Lung Dis (1999) 1.35
Microarray analysis of efflux pump genes in multidrug-resistant Mycobacterium tuberculosis during stress induced by common anti-tuberculous drugs. Microb Drug Resist (2010) 1.35
Multidrug resistance of a porin deletion mutant of Mycobacterium smegmatis. Antimicrob Agents Chemother (2004) 1.34
Targeting the formation of the cell wall core of M. tuberculosis. Infect Disord Drug Targets (2007) 1.33
A Mycobacterium tuberculosis sigma factor network responds to cell-envelope damage by the promising anti-mycobacterial thioridazine. PLoS One (2010) 1.32
The MspA porin promotes growth and increases antibiotic susceptibility of both Mycobacterium bovis BCG and Mycobacterium tuberculosis. Microbiology (2004) 1.31
Complex inhibition of OmpF and OmpC bacterial porins by polyamines. J Biol Chem (1997) 1.30
Expression of a gene for a porin-like protein of the OmpA family from Mycobacterium tuberculosis H37Rv. J Bacteriol (1998) 1.30
Survival mechanisms of pathogenic Mycobacterium tuberculosis H37Rv. FEBS J (2010) 1.26
Membrane permeability and regulation of drug "influx and efflux" in enterobacterial pathogens. Curr Drug Targets (2008) 1.26
Cadaverine induces closing of E. coli porins. EMBO J (1995) 1.26
Assessment of efflux pump gene expression in a clinical isolate Mycobacterium tuberculosis by real-time reverse transcription PCR. Microb Drug Resist (2008) 1.25
A tetrameric porin limits the cell wall permeability of Mycobacterium smegmatis. J Biol Chem (2002) 1.23
mmpL7 gene of Mycobacterium tuberculosis is responsible for isoniazid efflux in Mycobacterium smegmatis. Antimicrob Agents Chemother (2005) 1.23
Contribution of efflux activity to isoniazid resistance in the Mycobacterium tuberculosis complex. Infect Genet Evol (2011) 1.22
Accumulation of rifampicin by Mycobacterium aurum, Mycobacterium smegmatis and Mycobacterium tuberculosis. J Antimicrob Chemother (2000) 1.21
Enhanced killing of intracellular multidrug-resistant Mycobacterium tuberculosis by compounds that affect the activity of efflux pumps. J Antimicrob Chemother (2007) 1.19
Overexpression and functional characterization of an ABC (ATP-binding cassette) transporter encoded by the genes drrA and drrB of Mycobacterium tuberculosis. Biochem J (2002) 1.19
The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol (2009) 8.13
High-sensitivity MALDI-MRM-MS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions. Anal Chem (2011) 1.64
Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. Antimicrob Agents Chemother (2011) 1.50
Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses. Immunol Rev (2015) 1.45
Herbal bioactivation: the good, the bad and the ugly. Life Sci (2004) 1.13
Reduced drug uptake in phenotypically resistant nutrient-starved nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother (2013) 1.10
Genetic polymorphisms in KCNQ1, HERG, KCNE1 and KCNE2 genes in the Chinese, Malay and Indian populations of Singapore. Br J Clin Pharmacol (2006) 1.02
Phenolic acid-mediated regulation of the padC gene, encoding the phenolic acid decarboxylase of Bacillus subtilis. J Bacteriol (2008) 1.01
Mycolic acids as diagnostic markers for tuberculosis case detection in humans and drug efficacy in mice. EMBO Mol Med (2011) 0.99
Pharmacogenetics approach to therapeutics. Clin Exp Pharmacol Physiol (2006) 0.98
Drug forgiveness and interpatient pharmacokinetic variability in tuberculosis. J Infect Dis (2011) 0.91
Experimental tuberculosis in the Wistar rat: a model for protective immunity and control of infection. PLoS One (2011) 0.86
Multiplexed genotyping of ABC transporter polymorphisms with the Bioplex suspension array. Biol Proced Online (2007) 0.86
Effect of mushroom diet on pharmacokinetics of gabapentin in healthy Chinese subjects. Br J Clin Pharmacol (2014) 0.86
Simultaneous determination of raltegravir and raltegravir glucuronide in human plasma by liquid chromatography-tandem mass spectrometric method. J Mass Spectrom (2011) 0.86
Mycobacterium tuberculosis infection induces hypoxic lung lesions in the rat. Tuberculosis (Edinb) (2011) 0.84
Genetic variations of the SLCO1B1 gene in the Chinese, Malay and Indian populations of Singapore. Drug Metab Pharmacokinet (2008) 0.83
Genetic variations of the SLC22A4 gene in Chinese and Indian populations of Singapore. Drug Metab Pharmacokinet (2009) 0.83
Genetic variability of arylalkylamine-N-acetyl-transferase (AA-NAT) gene and human sleep/wake pattern. Chronobiol Int (2004) 0.83
Genetic variability of RyR2 and CASQ2 genes in an Asian population. Forensic Sci Int (2009) 0.82
Polyamines inhibit porin-mediated fluoroquinolone uptake in mycobacteria. PLoS One (2013) 0.82
Interethnic differences of PEPT2 (SLC15A2) polymorphism distribution and associations with cephalexin pharmacokinetics in healthy Asian subjects. Eur J Clin Pharmacol (2008) 0.82
Functional analysis of pharmacogenetic variants of human organic cation/carnitine transporter 2 (hOCTN2) identified in Singaporean populations. Biochem Pharmacol (2011) 0.81
BCG induces protection against Mycobacterium tuberculosis infection in the Wistar rat model. PLoS One (2011) 0.80
Genetic variations in the MCT1 (SLC16A1) gene in the Chinese population of Singapore. Drug Metab Pharmacokinet (2009) 0.79
Effect of dietary purines on the pharmacokinetics of orally administered ribavirin. J Clin Pharmacol (2009) 0.79
Identification and functional analysis of variants in the human concentrative nucleoside transporter 2, hCNT2 (SLC28A2) in Chinese, Malays and Indians. Pharmacogenet Genomics (2007) 0.78
Functional analysis of novel variants in the organic cation/ergothioneine transporter 1 identified in Singapore populations. Mol Pharm (2013) 0.77
T cell monitoring of chemotherapy in experimental rat tuberculosis. Antimicrob Agents Chemother (2011) 0.77
Genetic variations of the SLC22A5 gene in the Chinese and Indian populations of Singapore. Drug Metab Pharmacokinet (2010) 0.77
Effects of sodium bicarbonate and ammonium chloride pre-treatments on PEPT2 (SLC15A2) mediated renal clearance of cephalexin in healthy subjects. Drug Metab Pharmacokinet (2010) 0.77
Weighted target interval stochastic control methods with global optimization and their applications in individualizing therapy. J Pharmacokinet Pharmacodyn (2007) 0.75
Sampling schedule design towards optimal drug monitoring for individualizing therapy. Comput Methods Programs Biomed (2005) 0.75
Identification of functional promoter haplotypes of human concentrative nucleoside transporter 2, hCNT2 (SLC28A2). Drug Metab Pharmacokinet (2009) 0.75
Genetic variations of the MCT4 (SLC16A3) gene in the Chinese and Indian populations of Singapore. Drug Metab Pharmacokinet (2012) 0.75
Breath alcohol elimination rate and Widmark factor derived from breath alcohol concentration in Chinese and Indians in Singapore. Alcohol Alcohol (2012) 0.75
A naturally occurring -263G/C variant of the human AA-NAT gene and overnight melatonin production. Mol Genet Metab (2004) 0.75